GSK has purposefully developed multiple inhaled combinations for asthma/COPD.
Inhaled combinations were central to our respiratory research strategy
Multiple candidates, clear decision points, determinations, organizational buy-in.
Fluticasone furoate, Vilanterol and Umeclidinium.
50 Phase 3 COPD studies and 13 years from last molecule to COPD triple launch.
Building the knowledge base and addressing patient needs
How was the particle size selected for Trelegy Ellipta (FF/UMEC/VI)